知镜 Cognispect · 医学文献与研究工作台

Roxadustat-loaded pH-sensitive Anionic Liposomes Ameliorating Experimental Colitis in Mice: Formulation, Cellular Uptake and In vivo Evaluation.

Kong G, Zheng Y, Lu Y, Liu Z, Cheng W.
Current drug delivery · 2026-07-16 · PMID 42473220

文献摘要

Introduction Roxadustat, an inhibitor of hypoxia-inducible factor prolyl hydroxylase, has therapeutic potential for colitis but is limited clinically by poor water solubility and rapid gastrointestinal absorption. This study aimed to develop a pH-responsive, intestinal-targeted nanocarrier to enhance its oral bioavailability and anti-colitis efficacy. Methods Roxadustat-loaded liposomes (ROX-LP) were prepared via thin-film hydration with DSPG-PEG2000, cholesterol, and sodium cholate, then coated with Kollicoat MAE 100 P to form ROX-MAE@LP. The formulation was evaluated for physicochemical properties, in vitro release, cellular uptake, pharmacokinetics, and in vivo therapeutic efficacy. Results ROX-MAE@LP showed excellent encapsulation and uniform spherical morphology, with pH-dependent release (markedly increased at pH 6.8 and 7.4). Enhanced cellular uptake was observed in Caco-2 cells under intestinal pH-mimicking conditions. In rats, the oral bioavailability of ROX-LP (150.32±9.22%) and ROX-MAE@LP (255.36±12.82%) was improved compared with roxadustat suspension, and ROX-MAE@LP had a prolonged mean residence time (14.66±1.97 h). In a murine dextran sulfate sodium-induced colitis model, ROX-MAE@LP alleviated inflammation, downregulated pro-inflammatory cytokines, and promoted mucosal repair, outperforming ROX-LP and free roxadustat. Discussion The pH-responsive coating and intestinal-targeted property of ROX-MAE@LP effectively address the poor solubility and rapid absorption of roxadustat, enhancing local intestinal concentration and therapeutic effect in colitis, showing high potential for oral inflammatory bowel disease therapy. Conclusion ROX-MAE@LP is an effective intestine-targeted delivery system that improves roxadustat's solubility, bioavailability and therapeutic outcomes in inflammatory bowel disease, while offering additional options for the development of novel roxadustat-based preparations and pHresponsive nanocarriers.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。